Security Snapshot

INVESCO EXCHANGE TRADED FD T - PHARMACEUTICALS (PJP) Institutional Ownership

CUSIP: 46137V662

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

121

Shares (Excl. Options)

1,458,467

Price

$103.76

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+820,141
Value change
+$85,075,040
Number of holders
121
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$106.26
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • PJP - INVESCO EXCHANGE TRADED FD T - PHARMACEUTICALS is tracked under CUSIP 46137V662.
  • 121 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 105 to 121 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $69,181,701 to $151,289,632.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 121 institutions filings for Q1 2026.

Open SEC evidence

Security key

46137V662

Latest holder period

Q1 2026

13F holders

121

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 121 institutional investors reported holding 1,458,467 shares of INVESCO EXCHANGE TRADED FD T - PHARMACEUTICALS (PJP).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
36
Latest
Q1 2026
Rows shown
1-25 of 36
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,458,467 $151,289,632 +$85,075,040 $103.76 121
2025 Q4 661,793 $69,181,701 +$2,208,978 $104.54 105
2025 Q3 638,030 $59,014,643 +$125,900 $92.49 93
2025 Q2 648,304 $51,793,796 -$4,348,337 $79.87 92
2025 Q1 686,556 $59,329,046 -$7,420,789 $86.61 96
2024 Q4 771,959 $63,800,712 +$984,893 $82.62 93
2024 Q3 759,068 $65,987,834 -$1,444,326 $86.97 97
2024 Q2 772,678 $63,597,132 -$4,040,264 $82.21 89
2024 Q1 850,599 $66,020,158 +$10,912,907 $80.16 93
2023 Q4 690,752 $52,571,098 -$3,529,113 $76.10 86
2023 Q3 718,716 $52,012,966 -$4,223,551 $72.37 82
2023 Q2 770,569 $58,279,520 -$7,369,268 $75.62 84
2023 Q1 864,587 $65,706,224 -$7,112,845 $76.00 86
2022 Q4 960,831 $75,515,897 +$1,189,802 $78.60 92
2022 Q3 968,120 $69,031,328 +$13,740,443 $71.30 79
2022 Q2 774,936 $58,099,507 +$1,531,676 $74.97 77
2022 Q1 750,950 $59,765,049 -$3,608,649 $79.59 83
2021 Q4 797,603 $64,683,241 -$11,337,748 $81.13 78
2021 Q3 943,943 $73,105,100 +$8,871,294 $77.37 92
2021 Q2 828,585 $66,678,384 -$232,033 $80.45 88
2021 Q1 831,812 $65,599,188 -$16,638,970 $78.88 86
2020 Q4 1,051,101 $75,081,504 -$5,092,016 $71.39 85
2020 Q3 1,129,485 $72,171,244 -$15,663,262 $63.87 83
2020 Q2 1,386,375 $89,733,993 +$423,042 $64.72 85
2020 Q1 1,371,396 $75,501,624 -$9,823,991 $55.01 84
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .